| Year |
Citation |
Score |
| 2020 |
Chu Y, Bartus RT, Manfredsson FP, Olanow CW, Kordower JH. Long-term post-mortem studies following neurturin gene therapy in patients with advanced Parkinson's disease. Brain : a Journal of Neurology. 143: 960-975. PMID 32203581 DOI: 10.1093/Brain/Awaa020 |
0.359 |
|
| 2019 |
Gross SK, Shim BS, Bartus RT, Deaver D, Mceachin Z, Betourne A, Boulis NM, Maragakis NJ. Focal and dose-dependent neuroprotection in ALS mice following AAV2-neurturin delivery. Experimental Neurology. 113091. PMID 31678350 DOI: 10.1016/J.Expneurol.2019.113091 |
0.344 |
|
| 2016 |
Bartus RT, Johnson EM. Clinical tests of neurotrophic factors for human neurodegenerative diseases, part 1: Where have we been and what have we learned? Neurobiology of Disease. PMID 27063798 DOI: 10.1016/J.Nbd.2016.03.027 |
0.368 |
|
| 2016 |
Bartus RT, Johnson EM. Clinical tests of neurotrophic factors for human neurodegenerative diseases, part 2: Where do we stand and where must we go next? Neurobiology of Disease. PMID 27063797 DOI: 10.1016/J.Nbd.2016.03.026 |
0.357 |
|
| 2016 |
Marks WJ, Baumann TL, Bartus RT. Long-Term Safety of Patients with Parkinson's Disease Receiving rAAV2-Neurturin (CERE-120) Gene Transfer. Human Gene Therapy. 27: 522-7. PMID 26711317 DOI: 10.1089/Hum.2015.134 |
0.33 |
|
| 2015 |
Olanow CW, Bartus RT, Volpicelli-Daley LA, Kordower JH. Trophic factors for Parkinson's disease: To live or let die. Movement Disorders : Official Journal of the Movement Disorder Society. 30: 1715-24. PMID 26769457 DOI: 10.1002/Mds.26426 |
0.32 |
|
| 2015 |
Warren Olanow C, Bartus RT, Baumann TL, Factor S, Boulis N, Stacy M, Turner DA, Marks W, Larson P, Starr PA, Jankovic J, Simpson R, Watts R, Guthrie B, Poston K, et al. Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double-blind, randomized, controlled trial. Annals of Neurology. 78: 248-57. PMID 26061140 DOI: 10.1002/Ana.24436 |
0.612 |
|
| 2015 |
Bartus RT, Kordower JH, Johnson EM, Brown L, Kruegel BR, Chu Y, Baumann TL, Lang AE, Olanow CW, Herzog CD. Post-mortem assessment of the short and long-term effects of the trophic factor neurturin in patients with α-synucleinopathies. Neurobiology of Disease. 78: 162-71. PMID 25841760 DOI: 10.1016/J.Nbd.2015.03.023 |
0.389 |
|
| 2014 |
Rafii MS, Baumann TL, Bakay RA, Ostrove JM, Siffert J, Fleisher AS, Herzog CD, Barba D, Pay M, Salmon DP, Chu Y, Kordower JH, Bishop K, Keator D, Potkin S, ... Bartus RT, et al. A phase1 study of stereotactic gene delivery of AAV2-NGF for Alzheimer's disease. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 10: 571-81. PMID 24411134 DOI: 10.1016/J.Jalz.2013.09.004 |
0.325 |
|
| 2014 |
Bartus RT, Weinberg MS, Samulski RJ. Parkinson's disease gene therapy: success by design meets failure by efficacy. Molecular Therapy : the Journal of the American Society of Gene Therapy. 22: 487-97. PMID 24356252 DOI: 10.1038/Mt.2013.281 |
0.332 |
|
| 2013 |
Kordower JH, Olanow CW, Dodiya HB, Chu Y, Beach TG, Adler CH, Halliday GM, Bartus RT. Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. Brain : a Journal of Neurology. 136: 2419-31. PMID 23884810 DOI: 10.1093/Brain/Awt192 |
0.347 |
|
| 2013 |
Herzog CD, Brown L, Kruegel BR, Wilson A, Tansey MG, Gage FH, Johnson EM, Bartus RT. Enhanced neurotrophic distribution, cell signaling and neuroprotection following substantia nigral versus striatal delivery of AAV2-NRTN (CERE-120). Neurobiology of Disease. 58: 38-48. PMID 23631873 DOI: 10.1016/J.Nbd.2013.04.011 |
0.351 |
|
| 2013 |
Bartus RT, Baumann TL, Siffert J, Herzog CD, Alterman R, Boulis N, Turner DA, Stacy M, Lang AE, Lozano AM, Olanow CW. Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients. Neurology. 80: 1698-701. PMID 23576625 DOI: 10.1212/Wnl.0B013E3182904Faa |
0.614 |
|
| 2013 |
Bartus RT, Baumann TL, Brown L, Kruegel BR, Ostrove JM, Herzog CD. Advancing neurotrophic factors as treatments for age-related neurodegenerative diseases: developing and demonstrating "clinical proof-of-concept" for AAV-neurturin (CERE-120) in Parkinson's disease. Neurobiology of Aging. 34: 35-61. PMID 22926166 DOI: 10.1016/J.Neurobiolaging.2012.07.018 |
0.378 |
|
| 2012 |
Bartus RT. Translating the therapeutic potential of neurotrophic factors to clinical 'proof of concept': a personal saga achieving a career-long quest. Neurobiology of Disease. 48: 153-78. PMID 22525569 DOI: 10.1016/J.Nbd.2012.04.004 |
0.36 |
|
| 2011 |
Herzog CD, Bishop KM, Brown L, Wilson A, Kordower JH, Bartus RT. Gene transfer provides a practical means for safe, long-term, targeted delivery of biologically active neurotrophic factor proteins for neurodegenerative diseases. Drug Delivery and Translational Research. 1: 361-82. PMID 25788422 DOI: 10.1007/S13346-011-0037-Z |
0.405 |
|
| 2011 |
Bartus RT, Brown L, Wilson A, Kruegel B, Siffert J, Johnson EM, Kordower JH, Herzog CD. Properly scaled and targeted AAV2-NRTN (neurturin) to the substantia nigra is safe, effective and causes no weight loss: support for nigral targeting in Parkinson's disease. Neurobiology of Disease. 44: 38-52. PMID 21704161 DOI: 10.1016/J.Nbd.2011.05.026 |
0.351 |
|
| 2011 |
Bartus RT, Herzog CD, Chu Y, Wilson A, Brown L, Siffert J, Johnson EM, Olanow CW, Mufson EJ, Kordower JH. Bioactivity of AAV2-neurturin gene therapy (CERE-120): differences between Parkinson's disease and nonhuman primate brains. Movement Disorders : Official Journal of the Movement Disorder Society. 26: 27-36. PMID 21322017 DOI: 10.1002/Mds.23442 |
0.377 |
|
| 2010 |
Marks WJ, Bartus RT, Siffert J, Davis CS, Lozano A, Boulis N, Vitek J, Stacy M, Turner D, Verhagen L, Bakay R, Watts R, Guthrie B, Jankovic J, Simpson R, et al. Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. The Lancet. Neurology. 9: 1164-72. PMID 20970382 DOI: 10.1016/S1474-4422(10)70254-4 |
0.61 |
|
| 2009 |
Herzog CD, Brown L, Gammon D, Kruegel B, Lin R, Wilson A, Bolton A, Printz M, Gasmi M, Bishop KM, Kordower JH, Bartus RT. Expression, bioactivity, and safety 1 year after adeno-associated viral vector type 2-mediated delivery of neurturin to the monkey nigrostriatal system support cere-120 for Parkinson's disease. Neurosurgery. 64: 602-12; discussion 6. PMID 19349823 DOI: 10.1227/01.Neu.0000340682.06068.01 |
0.406 |
|
| 2009 |
Ramaswamy S, McBride JL, Han I, Berry-Kravis EM, Zhou L, Herzog CD, Gasmi M, Bartus RT, Kordower JH. Intrastriatal CERE-120 (AAV-Neurturin) protects striatal and cortical neurons and delays motor deficits in a transgenic mouse model of Huntington's disease. Neurobiology of Disease. 34: 40-50. PMID 19150499 DOI: 10.1016/J.Nbd.2008.12.005 |
0.348 |
|
| 2009 |
Franz CK, Federici T, Yang J, Backus C, Oh SS, Teng Q, Carlton E, Bishop KM, Gasmi M, Bartus RT, Feldman EL, Boulis NM. Intraspinal cord delivery of IGF-I mediated by adeno-associated virus 2 is neuroprotective in a rat model of familial ALS. Neurobiology of Disease. 33: 473-81. PMID 19135533 DOI: 10.1016/J.Nbd.2008.12.003 |
0.301 |
|
| 2009 |
Bartus RT, Dean RL. Pharmaceutical treatment for cognitive deficits in Alzheimer's disease and other neurodegenerative conditions: exploring new territory using traditional tools and established maps. Psychopharmacology. 202: 15-36. PMID 19011839 DOI: 10.1007/S00213-008-1365-7 |
0.327 |
|
| 2009 |
Marks W, Bartus R, Siffert J, Starr P, Ostrem J, Stacy M, Boulis N, Vitek J, Verhagen L, Watts R, Jankovic J, Tagliati M, Stern M, Nutt J, Kordower J, et al. P2.113 Multicenter, randomized, double-blind, sham surgery-controlled study of intraputaminal AAV2-neurturin (CERE-120) for advanced Parkinson's disease (PD) Parkinsonism & Related Disorders. 15: S120. DOI: 10.1016/S1353-8020(09)70464-X |
0.587 |
|
| 2009 |
Bartus R, Herzog C, Bishop K, Chu Y, Mufson E, Kordower J. P2.112 Bioactivity of CERE-120 (AAV2-neurturin gene therapy) in advanced Parkinson's disease (PD): post-mortem analysis of two autopsy cases Parkinsonism & Related Disorders. 15: S119. DOI: 10.1016/S1353-8020(09)70463-8 |
0.307 |
|
| 2008 |
Herzog CD, Dass B, Gasmi M, Bakay R, Stansell JE, Tuszynski M, Bankiewicz K, Chen EY, Chu Y, Bishop K, Kordower JH, Bartus RT. Transgene expression, bioactivity, and safety of CERE-120 (AAV2-neurturin) following delivery to the monkey striatum. Molecular Therapy : the Journal of the American Society of Gene Therapy. 16: 1737-44. PMID 18728639 DOI: 10.1038/Mt.2008.170 |
0.385 |
|
| 2008 |
Bishop KM, Hofer EK, Mehta A, Ramirez A, Sun L, Tuszynski M, Bartus RT. Therapeutic potential of CERE-110 (AAV2-NGF): targeted, stable, and sustained NGF delivery and trophic activity on rodent basal forebrain cholinergic neurons. Experimental Neurology. 211: 574-84. PMID 18439998 DOI: 10.1016/J.Expneurol.2008.03.004 |
0.4 |
|
| 2008 |
Marks WJ, Ostrem JL, Verhagen L, Starr PA, Larson PS, Bakay RA, Taylor R, Cahn-Weiner DA, Stoessl AJ, Olanow CW, Bartus RT. Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial. The Lancet. Neurology. 7: 400-8. PMID 18387850 DOI: 10.1016/S1474-4422(08)70065-6 |
0.389 |
|
| 2007 |
Bartus RT, Herzog CD, Bishop K, Ostrove JM, Tuszynski M, Kordower JH, Gasmi M. Issues regarding gene therapy products for Parkinson's disease: the development of CERE-120 (AAV-NTN) as one reference point. Parkinsonism & Related Disorders. 13: S469-77. PMID 18267286 DOI: 10.1016/S1353-8020(08)70052-X |
0.371 |
|
| 2007 |
Gasmi M, Brandon EP, Herzog CD, Wilson A, Bishop KM, Hofer EK, Cunningham JJ, Printz MA, Kordower JH, Bartus RT. AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: long-term efficacy and tolerability of CERE-120 for Parkinson's disease. Neurobiology of Disease. 27: 67-76. PMID 17532642 DOI: 10.1016/J.Nbd.2007.04.003 |
0.73 |
|
| 2007 |
Herzog CD, Dass B, Holden JE, Stansell J, Gasmi M, Tuszynski MH, Bartus RT, Kordower JH. Striatal delivery of CERE-120, an AAV2 vector encoding human neurturin, enhances activity of the dopaminergic nigrostriatal system in aged monkeys. Movement Disorders : Official Journal of the Movement Disorder Society. 22: 1124-32. PMID 17443702 DOI: 10.1002/Mds.21503 |
0.398 |
|
| 2007 |
Ramaswamy S, McBride JL, Herzog CD, Brandon E, Gasmi M, Bartus RT, Kordower JH. Neurturin gene therapy improves motor function and prevents death of striatal neurons in a 3-nitropropionic acid rat model of Huntington's disease. Neurobiology of Disease. 26: 375-84. PMID 17336076 DOI: 10.1016/J.Nbd.2007.01.003 |
0.711 |
|
| 2007 |
Gasmi M, Herzog CD, Brandon EP, Cunningham JJ, Ramirez GA, Ketchum ET, Bartus RT. Striatal delivery of neurturin by CERE-120, an AAV2 vector for the treatment of dopaminergic neuron degeneration in Parkinson's disease. Molecular Therapy : the Journal of the American Society of Gene Therapy. 15: 62-8. PMID 17164776 DOI: 10.1038/Sj.Mt.6300010 |
0.73 |
|
| 2006 |
Kordower JH, Herzog CD, Dass B, Bakay RA, Stansell J, Gasmi M, Bartus RT. Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys. Annals of Neurology. 60: 706-15. PMID 17192932 DOI: 10.1002/Ana.21032 |
0.4 |
|
| 2006 |
McBride JL, Ramaswamy S, Gasmi M, Bartus RT, Herzog CD, Brandon EP, Zhou L, Pitzer MR, Berry-Kravis EM, Kordower JH. Viral delivery of glial cell line-derived neurotrophic factor improves behavior and protects striatal neurons in a mouse model of Huntington's disease. Proceedings of the National Academy of Sciences of the United States of America. 103: 9345-50. PMID 16751280 DOI: 10.1073/Pnas.0508875103 |
0.71 |
|
| 2004 |
Bartus RT, Emerich D, Snodgrass-Belt P, Fu K, Salzberg-Brenhouse H, Lafreniere D, Novak L, Lo ES, Cooper T, Basile AS. A pulmonary formulation of L-dopa enhances its effectiveness in a rat model of Parkinson's disease. The Journal of Pharmacology and Experimental Therapeutics. 310: 828-35. PMID 15039453 DOI: 10.1124/Jpet.103.064121 |
0.304 |
|
| 2004 |
Landers M, Kwok K, Ketchum E, Wilson C, Lin R, Gammon D, Austin M, Manlapaz L, Wilson A, Cunningham J, Vacante D, Gasmi M, Bishop K, Printz M, Bartus R. 539. Biodistribution and safety profile of CERE-110 (AAV2-NGF) delivered to the rodent brain Molecular Therapy. 11. DOI: 10.1016/J.Ymthe.2004.06.667 |
0.364 |
|
| 2004 |
Ramirez A, Hao J, Kethchum E, Kwok K, Vacante D, Bartus R, Gasmi M. 536. Design and production of an AAV2 vector encoding a chimeric cDNA allowing efficient secretion of functional human neurturin from human cells Molecular Therapy. 9. DOI: 10.1016/J.Ymthe.2004.06.661 |
0.32 |
|
| 2004 |
Bishop KM, Hofer K, Rius D, Mehta A, Lawandry S, Brown L, Kruegel B, Gasmi M, Tuszynski M, Bartus RT. 527. CERE-110, an AAV2-based vector to deliver NGF, provides trophic activity to basal forebrain cholinergic neurons in rats and cynomolgous monkeys Molecular Therapy. 9. DOI: 10.1016/J.Ymthe.2004.06.473 |
0.386 |
|
| 2004 |
Herzog CD, Gasmi M, Cunningham JJ, Brandon EP, Ramirez A, Wilson A, Hofer EK, Hwang J, Manlapaz L, Kordower JH, Ostrove JM, Bartus RT. 227. Anatomical and Behavioral Effects of AAV2-Mediated Delivery of Neurturin to the Rat Striatum Prior to 6-Hydroxydopamine Induced Nigrostriatal Degeneration Molecular Therapy. 9. DOI: 10.1016/J.Ymthe.2004.06.172 |
0.728 |
|
| 2003 |
Salzberg-Brenhouse HC, Chen EY, Emerich DF, Baldwin S, Hogeland K, Ranelli S, Lafreniere D, Perdomo B, Novak L, Kladis T, Fu K, Basile AS, Kordower JH, Bartus RT. Inhibitors of cyclooxygenase-2, but not cyclooxygenase-1 provide structural and functional protection against quinolinic acid-induced neurodegeneration. The Journal of Pharmacology and Experimental Therapeutics. 306: 218-28. PMID 12676885 DOI: 10.1124/Jpet.103.049700 |
0.319 |
|
| 2002 |
Borlongan CV, Emerich DF, Hoffer BJ, Bartus RT. Bradykinin receptor agonist facilitates low-dose cyclosporine-A protection against 6-hydroxydopamine neurotoxicity. Brain Research. 956: 211-20. PMID 12445688 DOI: 10.1016/S0006-8993(02)03474-1 |
0.355 |
|
| 2002 |
Emerich DF, Winn SR, Bartus RT. Injection of chemotherapeutic microspheres and glioma. IV: Eradicating tumors in rats. Cell Transplantation. 11: 47-54. PMID 12095219 DOI: 10.3727/096020198389771 |
0.32 |
|
| 2002 |
Barth RF, Yang W, Bartus RT, Rotaru JH, Ferketich AK, Moeschberger ML, Nawrocky MM, Coderre JA, Rofstad EK. Neutron capture therapy of intracerebral melanoma: enhanced survival and cure after blood-brain barrier opening to improve delivery of boronophenylalanine. International Journal of Radiation Oncology, Biology, Physics. 52: 858-68. PMID 11849812 DOI: 10.1016/S0360-3016(01)02734-1 |
0.579 |
|
| 2001 |
Emerich DF, Dean RL, Osborn C, Bartus RT. The development of the bradykinin agonist labradimil as a means to increase the permeability of the blood-brain barrier: from concept to clinical evaluation. Clinical Pharmacokinetics. 40: 105-23. PMID 11286321 DOI: 10.2165/00003088-200140020-00003 |
0.322 |
|
| 2000 |
Emerich DF, Dean RL, Marsh J, Pink M, Lafreniere D, Snodgrass P, Bartus RT. Intravenous cereport (RMP-7) enhances delivery of hydrophilic chemotherapeutics and increases survival in rats with metastatic tumors in the brain. Pharmaceutical Research. 17: 1212-9. PMID 11145226 DOI: 10.1023/A:1026462629438 |
0.304 |
|
| 2000 |
Yang W, Barth RF, Bartus RT, Rotaru JH, Moeschberger ML, Ferketich AK, Nawrocky MM, Coderre JA, Goodman JH. Improved survival after boron neutron capture therapy of brain tumors by Cereport-mediated blood-brain barrier modulation to enhance delivery of boronophenylalanine. Neurosurgery. 47: 189-97; discussion 1. PMID 10917362 DOI: 10.1097/00006123-200007000-00039 |
0.559 |
|
| 2000 |
Bartus RT. On neurodegenerative diseases, models, and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis. Experimental Neurology. 163: 495-529. PMID 10833325 DOI: 10.1006/Exnr.2000.7397 |
0.309 |
|
| 2000 |
Saatman KE, Zhang C, Bartus RT, McIntosh TK. Behavioral efficacy of posttraumatic calpain inhibition is not accompanied by reduced spectrin proteolysis, cortical lesion, or apoptosis. Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism. 20: 66-73. PMID 10616794 DOI: 10.1097/00004647-200001000-00010 |
0.323 |
|
| 1999 |
Dean RL, Emerich DF, Hasler BP, Bartus RT. Cereport (RMP-7) increases carboplatin levels in brain tumors after pretreatment with dexamethasone. Neuro-Oncology. 1: 268-74. PMID 11550318 DOI: 10.1093/Neuonc/1.4.268 |
0.305 |
|
| 1999 |
Barth RF, Yang W, Bartus RT, Moeschberger ML, Goodman JH. Enhanced delivery of boronophenylalanine for neutron capture therapy of brain tumors using the bradykinin analog Cereport (Receptor-Mediated Permeabilizer-7). Neurosurgery. 44: 351-9; discussion 35. PMID 9932889 DOI: 10.1097/00006123-199902000-00062 |
0.514 |
|
| 1998 |
Granholm AC, Albeck D, Bäckman C, Curtis M, Ebendal T, Friden P, Henry M, Hoffer B, Kordower J, Rose GM, Söderström S, Bartus RT. A non-invasive system for delivering neural growth factors across the blood-brain barrier: a review. Reviews in the Neurosciences. 9: 31-55. PMID 9683326 DOI: 10.1515/Revneuro.1998.9.1.31 |
0.384 |
|
| 1998 |
LeMay DR, Kittaka M, Gordon EM, Gray B, Stins MF, McComb JG, Jovanovic S, Tabrizi P, Weiss MH, Bartus R, Anderson WF, Zlokovic BV. Intravenous RMP-7 increases delivery of ganciclovir into rat brain tumors and enhances the effects of herpes simplex virus thymidine kinase gene therapy. Human Gene Therapy. 9: 989-95. PMID 9607410 DOI: 10.1089/Hum.1998.9.7-989 |
0.308 |
|
| 1997 |
Bäckman C, Rose GM, Bartus RT, Hoffer BJ, Mufson EJ, Granholm AC. Carrier mediated delivery of NGF: alterations in basal forebrain neurons in aged rats revealed using antibodies against low and high affinity NGF receptors. The Journal of Comparative Neurology. 387: 1-11. PMID 9331167 DOI: 10.1002/(Sici)1096-9861(19971013)387:1<1::Aid-Cne1>3.0.Co;2-5 |
0.34 |
|
| 1996 |
Charles V, Mufson EJ, Friden PM, Bartus RT, Kordower JH. Atrophy of cholinergic basal forebrain neurons following excitotoxic cortical lesions is reversed by intravenous administration of an NGF conjugate. Brain Research. 728: 193-203. PMID 8864482 DOI: 10.1016/0006-8993(96)00398-8 |
0.337 |
|
| 1996 |
Bäckman C, Rose GM, Hoffer BJ, Henry MA, Bartus RT, Friden P, Granholm AC. Systemic administration of a nerve growth factor conjugate reverses age-related cognitive dysfunction and prevents cholinergic neuron atrophy. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 16: 5437-42. PMID 8757256 DOI: 10.1523/Jneurosci.16-17-05437.1996 |
0.362 |
|
| 1996 |
Saatman KE, Murai H, Bartus RT, Smith DH, Hayward NJ, Perri BR, McIntosh TK. Calpain inhibitor AK295 attenuates motor and cognitive deficits following experimental brain injury in the rat. Proceedings of the National Academy of Sciences of the United States of America. 93: 3428-33. PMID 8622952 DOI: 10.1073/Pnas.93.8.3428 |
0.34 |
|
| 1994 |
Kordower JH, Charles V, Bayer R, Bartus RT, Putney S, Walus LR, Friden PM. Intravenous administration of a transferrin receptor antibody-nerve growth factor conjugate prevents the degeneration of cholinergic striatal neurons in a model of Huntington disease. Proceedings of the National Academy of Sciences of the United States of America. 91: 9077-80. PMID 8090772 DOI: 10.1073/Pnas.91.19.9077 |
0.346 |
|
| 1990 |
Flicker C, Ferris SH, Crook T, Bartus RT. Impaired facial recognition memory in aging and dementia. Alzheimer Disease and Associated Disorders. 4: 43-54. PMID 2317337 DOI: 10.1097/00002093-199040100-00005 |
0.551 |
|
| 1989 |
Flicker C, Ferris SH, Crook T, Bartus RT. Age differences in the vulnerability of facial recognition memory to proactive interference. Experimental Aging Research. 15: 189-94. PMID 2638638 DOI: 10.1080/03610738908259774 |
0.538 |
|
| 1988 |
Flicker C, Ferris SH, Crook T, Reisberg B, Bartus RT. Equivalent spatial-rotation deficits in normal aging and Alzheimer's disease. Journal of Clinical and Experimental Neuropsychology. 10: 387-99. PMID 3403702 DOI: 10.1080/01688638808408247 |
0.541 |
|
| 1988 |
Bartus RT, Dean RL. Lack of efficacy of clonidine on memory in aged cebus monkeys. Neurobiology of Aging. 9: 409-11. PMID 3185860 DOI: 10.1016/S0197-4580(88)80089-7 |
0.364 |
|
| 1988 |
Bartus RT, Dean RL. Tetrahydroaminoacridine, 3,4 diaminopyridine and physostigmine: direct comparison of effects on memory in aged primates. Neurobiology of Aging. 9: 351-6. PMID 3185853 DOI: 10.1016/S0197-4580(88)80080-0 |
0.337 |
|
| 1988 |
Azmitia EC, Whitaker-Azmitia PM, Bartus R. Use of tissue culture models to study neuronal regulatory trophic and toxic factors in the aged brain. Neurobiology of Aging. 9: 743-58. PMID 3062480 DOI: 10.1016/S0197-4580(88)80142-8 |
0.315 |
|
| 1988 |
Bartus RT. The need for common perspectives in the development and use of animal models for age-related cognitive and neurodegenerative disorders. Neurobiology of Aging. 9: 445-51. PMID 3062456 DOI: 10.1016/S0197-4580(88)80097-6 |
0.34 |
|
| 1987 |
Flicker C, Ferris SH, Crook T, Bartus RT. A visual recognition memory test for the assessment of cognitive function in aging and dementia. Experimental Aging Research. 13: 127-32. PMID 3691582 DOI: 10.1080/03610738708259313 |
0.559 |
|
| 1987 |
Flicker C, Ferris SH, Crook T, Bartus RT. Implications of memory and language dysfunction in the naming deficit of senile dementia. Brain and Language. 31: 187-200. PMID 3620899 DOI: 10.1016/0093-934X(87)90069-1 |
0.539 |
|
| 1986 |
Bartus RT, Pontecorvo MJ, Flicker C, Dean RL, Figueiredo JC. Behavioral recovery following bilateral lesions of the nucleus basalis does not occur spontaneously. Pharmacology, Biochemistry, and Behavior. 24: 1287-92. PMID 3725831 DOI: 10.1016/0091-3057(86)90186-3 |
0.331 |
|
| 1986 |
Bartus RT, Flicker C, Dean RL, Fisher S, Pontecorvo M, Figueiredo J. Behavioral and biochemical effects of nucleus basalis magnocellularis lesions: implications and possible relevance to understanding or treating Alzheimer's disease. Progress in Brain Research. 70: 345-61. PMID 3554355 DOI: 10.1016/S0079-6123(08)64315-0 |
0.369 |
|
| 1986 |
Flicker C, Ferris SH, Reisberg B, Crook T, Bartus RT. Cognitive Decline in Advanced Age: Future Directions for the Psychometric Differentiation of Normal and Pathological Age Changes in Cognitive Function Developmental Neuropsychology. 2: 309-322. DOI: 10.1080/87565648609540351 |
0.518 |
|
| 1986 |
Crook T, Bartus RT, Ferris SH, Whitehouse P, Cohen GD, Gershon S. Age-Associated Memory Impairment: Proposed Diagnostic Criteria and Measures of Clinical Change—Report of a National Institute of Mental Health Work Group Developmental Neuropsychology. 2: 261-276. DOI: 10.1080/87565648609540348 |
0.514 |
|
| 1986 |
Flicker C, Ferris SH, Crook T, Bartus RT. The Effects of Aging and Dementia on Concept Formation As Measured on an Object-Sorting Task Developmental Neuropsychology. 2: 65-72. DOI: 10.1080/87565648609540328 |
0.53 |
|
| 1985 |
Bartus RT, Flicker C, Dean RL, Pontecorvo M, Figueiredo JC, Fisher SK. Selective memory loss following nucleus basalis lesions: long term behavioral recovery despite persistent cholinergic deficiencies. Pharmacology, Biochemistry, and Behavior. 23: 125-35. PMID 4041042 DOI: 10.1016/0091-3057(85)90139-X |
0.357 |
|
| 1985 |
Corwin J, Dean RL, Bartus RT, Rotrosen J, Watkins DL. Behavioral effects of phosphatidylserine in the aged Fischer 344 rat: amelioration of passive avoidance deficits without changes in psychomotor task performance. Neurobiology of Aging. 6: 11-5. PMID 4000381 DOI: 10.1016/0197-4580(85)90065-X |
0.341 |
|
| 1985 |
Flicker C, Dean R, Bartus RT, Ferris SH, Crook T. Animal and human memory dysfunctions associated with aging, cholinergic lesions, and senile dementia. Annals of the New York Academy of Sciences. 444: 515-7. PMID 3860113 DOI: 10.1111/J.1749-6632.1985.Tb37630.X |
0.545 |
|
| 1984 |
Flicker C, Bartus RT, Crook TH, Ferris SH. Effects of aging and dementia upon recent visuospatial memory. Neurobiology of Aging. 5: 275-83. PMID 6531065 DOI: 10.1016/0197-4580(84)90003-4 |
0.552 |
|
| 1983 |
Flicker C, Dean RL, Watkins DL, Fisher SK, Bartus RT. Behavioral and neurochemical effects following neurotoxic lesions of a major cholinergic input to the cerebral cortex in the rat. Pharmacology, Biochemistry, and Behavior. 18: 973-81. PMID 6889421 DOI: 10.1016/S0091-3057(83)80023-9 |
0.326 |
|
| 1983 |
Loullis CC, Dean RL, Lippa AS, Meyerson LR, Beer B, Bartus RT. Chronic administration of cholinergic agents: effects on behavior and calmodulin. Pharmacology, Biochemistry, and Behavior. 18: 601-4. PMID 6867065 DOI: 10.1016/0091-3057(83)90287-3 |
0.326 |
|
| 1983 |
Joseph JA, Bartus RT, Clody D, Morgan D, Finch C, Beer B, Sesack S. Psychomotor performance in the senescent rodent: reduction of deficits via striatal dopamine receptor up-regulation. Neurobiology of Aging. 4: 313-9. PMID 6687001 DOI: 10.1016/0197-4580(83)90008-8 |
0.35 |
|
| 1982 |
Bartus RT, Dean RL, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science (New York, N.Y.). 217: 408-14. PMID 7046051 DOI: 10.1126/Science.7046051 |
0.328 |
|
| 1982 |
Bartus RT, Dean RL, Beer B. Neuropeptide effects on memory in aged monkeys. Neurobiology of Aging. 3: 61-8. PMID 6124893 DOI: 10.1016/0197-4580(82)90062-8 |
0.367 |
|
| 1982 |
Reisberg MDB, Ferris SH, Schneck MK, Corwin J, Mir P, Friedman E, Sherman KA, McCarthy M, Bartus RT. Piracetam in the treatment of cognitive impairment in the elderly Drug Development Research. 2: 475-480. DOI: 10.1002/Ddr.430020508 |
0.546 |
|
| 1981 |
Dean RL, Scozzafava J, Goas JA, Regan B, Beer B, Bartus RT. Age-related differences in behavior across the life span of the C57BL/6J mouse. Experimental Aging Research. 7: 427-51. PMID 7333338 DOI: 10.1080/03610738108259823 |
0.33 |
|
| 1981 |
Bartus RT, Dean RL, Sherman KA, Friedman E, Beer B. Profound effects of combining choline and piracetam on memory enhancement and cholinergic function in aged rats. Neurobiology of Aging. 2: 105-11. PMID 7301036 DOI: 10.1016/0197-4580(81)90007-5 |
0.403 |
|
| 1981 |
Friedman E, Sherman KA, Ferris SH, Reisberg B, Bartus RT, Schneck MK. Clinical response to choline plus piracetam in senile dementia: relation to red-cell choline level. The New England Journal of Medicine. 304: 1490-1. PMID 7231482 DOI: 10.1056/NEJM198106113042413 |
0.455 |
|
| 1981 |
Sherman KA, Kuster JE, Dean RL, Bartus RT, Friedman E. Presynaptic cholinergic mechanisms in brain of aged rats with memory impairments. Neurobiology of Aging. 2: 99-104. PMID 7197758 DOI: 10.1016/0197-4580(81)90006-3 |
0.378 |
|
| 1981 |
Lippa AS, Critchett DJ, Ehlert F, Yamamura HI, Enna SJ, Bartus RT. Age-related alterations in neurotransmitter receptors: an electrophysiological and biochemical analysis. Neurobiology of Aging. 2: 3-8. PMID 6115325 DOI: 10.1016/0197-4580(81)90052-X |
0.383 |
|
| 1981 |
Ferris SH, Crook T, Bartus RT. Meeting report. Workshop on assessment for geriatric psychopharmacology Neurobiology of Aging. 2: 319-322. DOI: 10.1016/0197-4580(81)90042-7 |
0.473 |
|
| 1980 |
Bartus RT, Dean RL, Beer B. Memory deficits in aged cebus monkeys and facilitation with central cholinomimetics. Neurobiology of Aging. 1: 145-52. PMID 24279938 DOI: 10.1016/0197-4580(80)90008-1 |
0.368 |
|
| 1980 |
Strong R, Hicks P, Hsu L, Bartus RT, Enna SJ. Age-related alterations in the rodent brain cholinergic system and behavior. Neurobiology of Aging. 1: 59-63. PMID 7266736 DOI: 10.1016/0197-4580(80)90025-1 |
0.349 |
|
| 1980 |
Lippa AS, Pelham RW, Beer B, Critchett DJ, Dean RL, Bartus RT. Brain cholinergic dysfunction and memory in aged rats. Neurobiology of Aging. 1: 13-9. PMID 7266730 DOI: 10.1016/0197-4580(80)90019-6 |
0.349 |
|
| 1979 |
Bartus RT. Physostigmine and recent memory: effects in young and aged nonhuman primates. Science (New York, N.Y.). 206: 1087-9. PMID 227061 DOI: 10.1126/Science.227061 |
0.357 |
|
| 1979 |
Bartus RT, Dean RL. Recent memory in aged non-human primates: hypersensitivity to visual interference during retention. Experimental Aging Research. 5: 385-400. PMID 118012 DOI: 10.1080/03610737908257214 |
0.329 |
|
| 1979 |
Marriott JG, Bartus RT, Moyer C, Voigtman RE. The effects of blood sludging upon short-term memory in rats and rhesus monkeys: an evaluation of its role in age-related cognitive declines. Physiology & Behavior. 22: 715-22. PMID 113794 DOI: 10.1016/0031-9384(79)90237-3 |
0.765 |
|
| 1979 |
Bartus RT. Four stimulants of the central nervous system: effects on short-term memory in young versus aged monkeys. Journal of the American Geriatrics Society. 27: 289-97. PMID 36423 DOI: 10.1111/J.1532-5415.1979.Tb06042.X |
0.368 |
|
| 1978 |
Bartus RT. Evidence for a direct cholinergic involvement in the scopolamine-induced amnesia in monkeys: effects of concurrent administration of physostigmine and methylphenidate with scopolamine. Pharmacology, Biochemistry, and Behavior. 9: 833-6. PMID 106402 DOI: 10.1016/0091-3057(78)90364-7 |
0.337 |
|
| 1978 |
Bartus RT, Fleming D, Johnson HR. Aging in the rhesus monkey: debilitating effects on short-term memory. Journal of Gerontology. 33: 858-71. PMID 106081 DOI: 10.1093/Geronj/33.6.858 |
0.351 |
|
| 1978 |
Bartus RT. Short-term memory in the rhesus monkey: effects of dopamine blockade via acute haloperidol administration. Pharmacology, Biochemistry, and Behavior. 9: 353-7. PMID 101990 DOI: 10.1016/0091-3057(78)90296-4 |
0.375 |
|
| 1976 |
Bartus RT, Johnson HR. Short-term memory in the rhesus monkey: disruption from the anti-cholinergic scopolamine. Pharmacology, Biochemistry, and Behavior. 5: 39-46. PMID 825880 DOI: 10.1016/0091-3057(76)90286-0 |
0.329 |
|
| 1974 |
Bartus RT, Ferris SH. Neural correlates of habituation and dark adaptation in the visual cortex of the rat Physiological Psychology. 2: 55-59. DOI: 10.3758/BF03332992 |
0.433 |
|
| Show low-probability matches. |